Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum.

BACKGROUND Saccharomyces boulardii is a nonpathogenic yeast used for the prevention and treatment of Clostridium difficile-associated diarrhea and colitis. However, the mechanism by which S. boulardii exerts its protective effects remains unclear. METHODS The binding of [3H]toxin A to its brush border receptor preincubated with S. boulardii-cultured suspension or filtered conditioned medium was measured in vitro. The effect of toxin A on secretion, epithelial permeability, and morphology in rat ileal loops in vivo was also examined in rats pretreated with S. boulardii. RESULTS S. boulardii reduced [3H]toxin A-receptor binding in a dose-dependent fashion. Sodium dodecyl sulfate polyacrylamide gel electrophoresis of ileal brush border exposed to S. boulardii-conditioned medium revealed a diminution of all brush border proteins. Treatment of rats with S. boulardii suspension reduced fluid secretion and mannitol permeability caused by toxin A. CONCLUSIONS S. boulardii may reduce some of the enterotoxic effects of toxin A by inhibiting toxin A-receptor binding. This effect appears to be manifested by a secreted product of the yeast, possibly a protease.

[1]  I. Ohishi.  Response of mouse intestinal loop to botulinum C2 toxin: enterotoxic activity induced by cooperation of nonlinked protein components , 1983, Infection and immunity.

[2]  C. Surawicz,et al.  Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii. , 1989, The American journal of gastroenterology.

[3]  P. Rampal,et al.  [Response of the IRD intestinal epithelial cell line to Clostridium difficile toxins A and B in rats. Effect of Saccharomyces boulardii]. , 1991, Gastroenterologie clinique et biologique.

[4]  G. Corthier,et al.  Modulation of Clostridium difficile induced mortality as a function of the dose and the viability of the Saccharomyces boulardii used as a preventative agent in gnotobiotic mice. , 1991, Canadian journal of microbiology.

[5]  M. Craynest,et al.  Response of Human and Rat Small Intestinal Mucosa to Oral Administration of Saccharomyces boulardii , 1986, Pediatric Research.

[6]  S. Vishwanath,et al.  Antigenic relationships among the rickettsiae of the spotted fever and typhus groups. , 1991, FEMS microbiology letters.

[7]  R. Tweten,et al.  Purification and characterization of toxin B from Clostridium difficile , 1988, Infection and immunity.

[8]  J. Bartlett,et al.  Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. , 1977, The Journal of infectious diseases.

[9]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[10]  C. Giampaolo,et al.  Comparative study of Clostridium difficile toxin A and cholera toxin in rabbit ileum. , 1989, Gastroenterology.

[11]  C. Krishnan,et al.  Pathogenesis of mucosal injury in the blind loop syndrome: Release of disaccharidases from brush border membranes by extracts of bacteria obtained from intestinal blind loops in rats , 1978 .

[12]  G. Belle,et al.  Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. , 1989, Gastroenterology.

[13]  Esther Jacobowitz Israel,et al.  Diminished Clostridium difficile toxin A sensitivity in newborn rabbit ileum is associated with decreased toxin A receptor. , 1992, The Journal of clinical investigation.

[14]  C. von Eichel-Streiber,et al.  Clostridium difficile toxin A carries a C-terminal repetitive structure homologous to the carbohydrate binding region of streptococcal glycosyltransferases. , 1990, Gene.

[15]  T. Wilkins,et al.  Clostridium difficile: its disease and toxins , 1988, Clinical Microbiology Reviews.

[16]  G. Corthier,et al.  Prevention of Clostridium difficile induced mortality in gnotobiotic mice by Saccharomyces boulardii. , 1986, Canadian journal of microbiology.

[17]  L. Hoskins,et al.  Degradation of blood group antigens in human colon ecosystems. I. In vitro production of ABH blood group-degrading enzymes by enteric bacteria. , 1976, The Journal of clinical investigation.

[18]  K. James.  Alpha2 macroglobulin and its possible importance in immune systems , 1980 .

[19]  G. Clark,et al.  Cell surface binding site for Clostridium difficile enterotoxin: evidence for a glycoconjugate containing the sequence Gal alpha 1-3Gal beta 1-4GlcNAc , 1986, Infection and immunity.

[20]  R. Rolfe.  Binding kinetics of Clostridium difficile toxins A and B to intestinal brush border membranes from infant and adult hamsters , 1991, Infection and immunity.

[21]  M. O'brien,et al.  Differential effects of Clostridium difficile toxins A and B on rabbit ileum. , 1987, Gastroenterology.

[22]  S. Nakamura,et al.  Production of monoclonal antibody to Clostridium difficile toxin A which neutralizes enterotoxicity but not haemagglutination activity. , 1991, FEMS microbiology letters.

[23]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[24]  J. Bartlett,et al.  Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. , 1978, The New England journal of medicine.

[25]  A. Parodi,et al.  Bacterio-pharmacological activity of Saccharomyces boulardii in clindamycin-induced colitis in the hamster. , 1984, Arzneimittel-Forschung.

[26]  G. Elmer,et al.  Prevention of clindamycin-induced mortality in hamsters by Saccharomyces boulardii , 1984, Antimicrobial Agents and Chemotherapy.

[27]  J. Johnson,et al.  Molecular characterization of the Clostridium difficile toxin A gene , 1990, Infection and immunity.

[28]  C. Krishnan,et al.  Pathogenesis of mucosal injury in the blind loop syndrome. , 1978, Gastroenterology.

[29]  C. Pothoulakis,et al.  Characterization of rabbit ileal receptors for Clostridium difficile toxin A. Evidence for a receptor-coupled G protein. , 1991, The Journal of clinical investigation.

[30]  N. Sullivan,et al.  Purification and characterization of toxins A and B of Clostridium difficile , 1982, Infection and immunity.

[31]  A. Barrett.  [54] α2-Macroglobulin , 1981 .

[32]  E. Jennische,et al.  Enterotoxins from Clostridium difficile; diarrhoeogenic potency and morphological effects in the rat intestine. , 1990, Gut.

[33]  G. Corthier,et al.  Prevention of Clostridium difficile-induced experimental pseudomembranous colitis by Saccharomyces boulardii: a scanning electron microscopic and microbiological study. , 1990, Journal of general microbiology.

[34]  N. Vidon,et al.  [Influence of Saccharomyces boulardii on jejunal secretion in rats induced by cholera toxin]. , 1986, Gastroenterologie clinique et biologique.

[35]  K. Saum,et al.  Effects of Clostridium difficile toxins given intragastrically to animals , 1985, Infection and immunity.

[36]  G. Corthier,et al.  Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A , 1991, Infection and immunity.